The firm's financial position is characterized by a massive accumulated deficit of $792.7 million, leaving the company with minimal tangible assets beyond its $229.1 million cash balance.
| Total Current Assets | 285.02M | 323.67M | 189.43M | 464.67M | 382.13M | 104.95M | 13.64M | 3.2M |
| Cash & Short-Term Investments | 279.77M | 316.98M | 176.5M | 371.36M | 346.94M | 96.12M | 12.88M | 3.06M |
| Cash Only | 229.14M | 226.65M | 77.39M | 170.2M | 62.53M | 50.19M | 12.88M | 3.06M |
| Short-Term Investments | 50.63M | 90.33M | 99.11M | 201.16M | 284.42M | 45.93M | 0 | 0 |
| Accounts Receivable | 0 | 88K | 447K | 40.05M | 15.31M | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | 1.87 | 38.39 | 251.31 | - | - | - |
| Inventory | 0 | 0 | 0 | 38.32M | 9.77M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | 549.82 | 1.19K | - | - | - |
| Other Current Assets | 5.26M | 6.6M | 12.48M | 14.93M | 10.11M | 3.44M | 0 | 26K |
| Total Non-Current Assets | 8.58M | 8.97M | 4.2M | 52.79M | 9.32M | 663K | 465K | 18K |
| Property, Plant & Equipment | 5.09M | 5.49M | 2.73M | 6.41M | 8.13M | 474K | 151K | 0 |
| Fixed Asset Turnover | 0.00x | - | 31.98x | 59.40x | 2.73x | - | 4.30x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 2.43M | 0 | 0 | 0 | 0 | 0 | 189K | 0 |
| Other Non-Current Assets | 3.49M | 3.48M | 1.47M | 46.38M | 1.19M | 189K | 125K | 18K |
| Total Assets | 293.6M | 332.64M | 193.63M | 517.45M | 391.45M | 105.61M | 14.1M | 3.22M |
| Asset Turnover | 0.00x | - | 0.45x | 0.74x | 0.06x | - | 0.05x | 0.44x |
| Asset Growth % | 108.71% | 71.79% | -62.58% | 32.19% | 270.64% | 648.82% | 338.01% | - |
| Total Current Liabilities | 15.97M | 22.69M | 28.41M | 82.04M | 46.61M | 17.4M | 7.33M | 4.53M |
| Accounts Payable | 3.53M | 3.52M | 2.94M | 22.06M | 6.26M | 4.37M | 3.61M | 2.19M |
| Days Payables Outstanding | 70.83 | 2.45K | 25.45 | 316.51 | 763.05 | - | 53.62 | 67.33 |
| Short-Term Debt | 1.16M | 1.26M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.28M | 17.91M | 9.99M | 40.93M | 15.23M | 4.28M | 0 | 652K |
| Current Ratio | 17.85x | 14.27x | 6.67x | 5.66x | 8.20x | 6.03x | 1.86x | 0.71x |
| Quick Ratio | 17.85x | 14.27x | 6.67x | 5.20x | 7.99x | 6.03x | 1.86x | 0.71x |
| Cash Conversion Cycle | - | - | - | 271.7 | 679.61 | - | - | - |
| Total Non-Current Liabilities | 4.48M | 4.7M | 463K | 1.98M | 4.24M | 239.39M | 73.5M | 24.05M |
| Long-Term Debt | 4.48M | 4.7M | 0 | 0 | 0 | 0 | 1.43M | 14.93M |
| Capital Lease Obligations | 10.25M | 0 | 463K | 1.98M | 4.24M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 239.39M | 72.06M | 9.11M |
| Total Liabilities | 20.44M | 27.39M | 28.87M | 84.02M | 50.85M | 256.78M | 80.83M | 28.58M |
| Total Debt | 5.63M | 5.96M | 1.98M | 4.24M | 6.28M | 0 | 1.43M | 14.93M |
| Net Debt | -223.5M | -220.69M | -75.41M | -165.96M | -56.25M | -50.19M | -11.45M | 11.87M |
| Debt / Equity | 0.02x | 0.02x | 0.01x | 0.01x | 0.02x | - | - | - |
| Debt / EBITDA | -0.04x | - | - | 0.11x | - | - | - | - |
| Net Debt / EBITDA | 1.41x | - | - | -4.16x | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | -17.05x | -9.75x |
| Total Equity | 273.16M | 305.26M | 164.76M | 433.43M | 340.61M | -151.17M | -66.72M | -25.36M |
| Equity Growth % | 154.34% | 85.27% | -61.99% | 27.25% | 325.32% | -126.55% | -163.14% | - |
| Book Value per Share | 2.47 | 3.23 | 2.42 | 6.19 | 5.12 | -2.61 | -1.18 | -0.45 |
| Total Shareholders' Equity | 273.16M | 305.26M | 164.76M | 433.43M | 340.61M | -151.17M | -66.72M | -25.36M |
| Common Stock | 11K | 11K | 7K | 7K | 7K | 1K | 1K | 1K |
| Retained Earnings | -792.71M | -751.43M | -606.69M | -304.95M | -354.22M | -155.84M | -67.91M | -25.63M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 240K | 404K | -92K | 197K | -86K | 9K | -72.06M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical trial funding exhaustion
As reported in financial statements, Amylyx's total assets have declined from a peak of $517.5 million in 2023Q4 to $293.6 million by 2026Q1, reflecting a rapid contraction in the company's resource base following the voluntary market withdrawal of its primary commercial product, Relyvrio.
The consistent decline in total assets suggests a company in the midst of a significant downsizing phase as it pivots away from commercial operations. Investors should monitor whether this trajectory stabilizes as the firm shifts its focus entirely toward clinical-stage development, or if further asset liquidation is required to fund ongoing trials.
Based on recent quarterly filings, the company's cash position has fluctuated significantly, ending 2026Q1 at $229.1 million, which provides a temporary buffer but remains under pressure as the firm continues to fund its clinical pipeline without any offsetting commercial revenue streams to support operations.
While the current ratio of 17.85 appears superficially strong, it is largely a function of the lack of short-term commercial liabilities rather than operational strength. The rapid depletion of cash reserves observed in mid-2025 highlights the precarious nature of the firm's liquidity, which may necessitate future capital raises if clinical milestones are delayed.
According to the balance sheet data, retained earnings have plummeted to a deficit of $792.7 million as of 2026Q1, illustrating the severe impact of sustained operational losses and the write-down of commercial assets on the company's total equity position over the past ten quarters.
The persistent growth of the accumulated deficit suggests that the company's historical capital allocation has failed to generate sustainable returns for shareholders. This trend warrants further investigation into whether the current clinical pipeline possesses the potential to reverse this erosion or if further dilution is inevitable to maintain operations.
As indicated by the reported figures, the company's asset base is almost entirely composed of cash and cash equivalents, with net PPE remaining negligible at $5.1 million, which suggests that the firm lacks tangible operational infrastructure to support a potential future commercial relaunch.
The absence of significant tangible assets implies that the company's value is tied exclusively to its intellectual property and clinical trial outcomes. This lack of physical operational depth makes the firm highly sensitive to regulatory setbacks, as there are few tangible assets to provide a floor for valuation in a worst-case scenario.
Quick answers to the most common questions about buying AMLX stock.
As of 2025, Amylyx Pharmaceuticals, Inc. (AMLX) had total assets of $332.6M including $323.7M in current assets.
Amylyx Pharmaceuticals, Inc. (AMLX) carries total debt of $6.0M, offset by $317.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Amylyx Pharmaceuticals, Inc. (AMLX) has total shareholders' equity (book value) of $305.3M ($3.23 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Amylyx Pharmaceuticals, Inc. (AMLX) reported a current ratio of 14.27x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.